The pharmaceutical laboratory Biogaran, leader in generic drugs in France, took part in a screening operation for cardio-metabolic diseases such as high blood pressure and diabetes, alongside health professionals from the health zone of Pobè, Adja-Ouèrè , Kétou (PAK), this Friday, March 17, 2023.
This action, which comes shortly following several awareness-raising and screening operations carried out in Côte d’Ivoire and the Democratic Republic of Congo (DRC), once once more reaffirms the laboratory’s commitment to optimal patient care. in Africa, and in particular in Benin, as well as access to quality healthcare throughout the country.
More than 500 patients attended this operation which was held in Pobè and which also welcomed the populations of neighboring towns such as Adja-Ouèrè, Ikpinlè, Onigbolo and Kétou. The objective of this screening was to raise public awareness of the risks posed by cardio-metabolic diseases to the health of patients and of the importance of performing screenings frequently in order to be offered adequate treatment in the event of a positive diagnosis. This operation particularly targeted the population of the South-East of the country, a rural region where the provision of care is limited and where communities can therefore suffer from high blood pressure and diabetes without knowing it.
These pathologies have continued to grow on the continent in recent years1, and particularly among patients in Benin. In this regard, the annual report of the World Health Organization (WHO) on Benin[1] of 2020 explains that high blood pressure affects more than a quarter of the population (25.90%) while the national prevalence rate of diabetes stood at just over 12.4% in 2015, a figure that is constantly growing .
Statistics that seem to justify the organization of this operation, led by general practitioners, gynecologists and nurses from the Plateau department, gathered within the Public-Private Partnership Consultation Framework of the PAK Health Zone (Pobè, Adja-Ouèrè, Ketou), himself. By participating in this type of initiative, Biogaran wishes to encourage the early detection of cardio-metabolic diseases and promote access to care for all patients in Benin.
Donald Tossa, Biogaran Manager in Benin, said: “The increase in the prevalence of cardio-metabolic diseases throughout Africa, and particularly in Benin, has become a worrying public health issue, which requires vigorous measures involving all healthcare professionals and partners. By making its reusable kits available to the Public-Private Partnership Consultation Framework organization of the PAK Health Zone, Biogaran aspires to contribute to the success of the campaigns carried out by the collective with the aim of reducing the health risks associated with diseases. cardio-metabolic for local populations. »
As a reminder, Biogaran has a wide range of drugs to treat cardio-metabolic diseases such as diabetes and hypertension but also cancerous diseases and some of the most common pathologies in the country such as infections for example. The Biogaran drugs available in Benin are produced in strict compliance with European standards and 91% manufactured in Europe and 51% in France.
In addition, the laboratory is committed to training local health professionals, in particular through the Biogaran Academy, a free continuing education program in the form of webinars organized every two months on various health topics. These training courses inform health professionals regarding the state of the art in medical matters and thus provide patients with optimal care.
Dr Da Cruz Paul, President of the Consultation Framework for the Public-Private Partnership of the PAK Health Zone: “The collaboration with Biogaran represents a significant step forward in renewing our screening campaigns and thus diagnosing more patients. This will also make it possible to give them access to the most appropriate treatment and to regularly raise their awareness of the health risks that high blood pressure and diabetes represent, especially if they are not screened. “.
It should be remembered that a sports walk was also organized on Thursday March 16, 2023, the day before this operation, followed by an intervention by health professionals whose mission was to educate patients on the importance of diabetes prevention. and arterial hypertension, as well as on the risks incurred in the event of late diagnosis of these pathologies.
About Biogaran
Founded in 1996, Biogaran is a leading pharmaceutical laboratory on the generic drug market in France, a subsidiary of the Servier group and headquartered in Colombes (France). Biogaran provides patients and healthcare professionals with know-how acquired over 25 years of activity. 91% of Biogaran drugs are produced in Europe and 51% in France in strict compliance with European manufacturing standards.
www.24haubenin.bj; real-time information
March 20, 2023 by
